Zytiga(abiraterone)
Abiraterone, Akeega, Yonsa, Zytiga (abiraterone) is a small molecule pharmaceutical. Abiraterone was first approved as Zytiga on 2011-04-28. It is used to treat castration-resistant prostatic neoplasms in the USA. It has been approved in Europe to treat castration-resistant prostatic neoplasms and prostatic neoplasms. The pharmaceutical is active against steroid 17-alpha-hydroxylase/17,20 lyase.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Abiraterone, Yonsa, Zytiga (discontinued: Abiraterone)
CombinationsAkeega
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Abiraterone acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZYTIGA | Johnson & Johnson | N-202379 RX | 2011-04-28 | 2 products, RLD |
| YONSA | Sun Pharmaceutical Industries | N-210308 RX | 2018-05-22 | 1 products, RLD, RS |
Abiraterone acetate
+
Niraparib tosylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AKEEGA | Johnson & Johnson | N-216793 RX | 2023-08-11 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abiraterone | ANDA | 2026-03-24 |
| abiraterone acetate | ANDA | 2026-10-05 |
| abirtega | ANDA | 2025-02-28 |
| akeega | New Drug Application | 2025-12-18 |
| yonsa | New Drug Application | 2026-06-08 |
| zytiga | New Drug Application | 2025-03-28 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ABIRATERONE ACETATE / NIRAPARIB TOSYLATE, AKEEGA, JANSSEN BIOTECH | |||
| 2026-08-11 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Abiraterone Acetate / Niraparib Tosylate, Akeega, Janssen Biotech | |||
| 11091459 | 2038-03-27 | DS, DP | |
| 11673877 | 2038-03-27 | DS, DP | |
| 11207311 | 2037-07-28 | U-2830 | |
| 8859562 | 2031-08-04 | U-2830 | |
| 8071623 | 2031-03-27 | DS, DP | |
| 8436185 | 2029-04-24 | DS, DP | |
| 8071579 | 2027-08-12 | U-2830 | |
| 8143241 | 2027-08-12 | U-2830 | |
| Abiraterone Acetate, Yonsa, Sun Pharm | |||
| 10292990 | 2034-05-20 | U-2535 | |
| 9889144 | 2034-03-17 | DP | |
HCPCS
No data
Clinical
Clinical Trials
486 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 96 | 216 | 62 | 6 | 64 | 400 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 41 | 73 | 27 | 4 | 17 | 139 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | — | 1 | — | 1 |
| Cognitive dysfunction | D060825 | — | G31.84 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | 5 | 24 | 2 | — | 4 | 34 |
| Neoplasms | D009369 | — | C80 | 13 | 8 | 3 | — | 4 | 23 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 5 | 9 | 5 | — | 6 | 22 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 7 | 1 | — | — | 12 |
| Colorectal neoplasms | D015179 | — | — | 6 | 2 | 1 | — | — | 7 |
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 2 | 1 | 1 | — | 1 | 4 |
| X-linked bulbo-spinal atrophy | D055534 | Orphanet_139557 | — | 2 | 2 | 2 | — | — | 4 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 2 | 1 | 1 | — | — | 3 |
| Recurrence | D012008 | — | — | — | — | 2 | — | 1 | 3 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 1 | — | 1 | — | — | 2 |
Show 4 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-small-cell lung carcinoma | D002289 | — | — | 8 | 5 | — | — | — | 10 |
| Carcinoma | D002277 | — | C80.0 | 1 | 7 | — | — | — | 8 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 4 | 1 | — | — | — | 4 |
| Melanoma | D008545 | — | — | 2 | 3 | — | — | — | 3 |
| Urologic neoplasms | D014571 | — | C64-C68 | 1 | 2 | — | — | — | 3 |
| Transitional cell carcinoma | D002295 | — | — | 1 | 2 | — | — | — | 3 |
| Myelodysplastic syndromes | D009190 | — | D46 | 3 | 2 | — | — | — | 3 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 2 | — | — | — | 3 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 2 | 2 | — | — | — | 3 |
| Small cell lung carcinoma | D055752 | — | — | 2 | 2 | — | — | — | 3 |
Show 37 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | — | — | — | — | 3 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | 2 | 3 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 2 | — | — | — | — | 2 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | — | — | — | — | 2 |
| Male genital diseases | D005832 | EFO_0009555 | N50.9 | 1 | — | — | — | 1 | 2 |
| Pharmacokinetics | D010599 | — | — | 2 | — | — | — | — | 2 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | — | 1 |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | — | — | — | — | 1 |
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
Show 21 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Disease resistance | D060467 | — | — | — | — | — | — | 1 | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | — | 1 | 1 |
| Pharmacogenomic testing | D000071185 | — | — | — | — | — | — | 1 | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | — | — | — | — | 1 | 1 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | — | — | 1 | 1 |
| Tachycardia | D013610 | — | R00.0 | — | — | — | — | 1 | 1 |
| Supraventricular tachycardia | D013617 | — | I47.1 | — | — | — | — | 1 | 1 |
| Genital diseases | D000091662 | — | — | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Abiraterone |
| INN | abiraterone |
| Description | Abiraterone acetate is a sterol ester obtained by formal condensation of the 3-hydroxy group of abiraterone with the carboxy group of acetic acid. A prodrug that is converted in vivo into abiraterone. Used for treatment of metastatic castrate-resistant prostate cancer. It has a role as a prodrug, an antineoplastic agent and an EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor. It is a sterol ester and a member of pyridines. It is functionally related to an abiraterone. |
| Classification | Small molecule |
| Drug class | antiandrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1 |
Identifiers
| PDB | — |
| CAS-ID | 154229-19-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL254328 |
| ChEBI ID | 68642 |
| PubChem CID | 9821849 |
| DrugBank | DBSALT001173 |
| UNII ID | G819A456D0 (ChemIDplus, GSRS) |
Target
Agency Approved
CYP17A1
CYP17A1
Organism
Homo sapiens
Gene name
CYP17A1
Gene synonyms
CYP17, S17AH
NCBI Gene ID
Protein name
steroid 17-alpha-hydroxylase/17,20 lyase
Protein synonyms
17-alpha-hydroxyprogesterone aldolase, CYPXVII, Cytochrome P450 17A1, cytochrome p450 XVIIA1, cytochrome P450, family 17, subfamily A, polypeptide 1, cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia, Cytochrome P450-C17, Cytochrome P450c17, Steroid 17-alpha-monooxygenase
Uniprot ID
Mouse ortholog
Cyp17a1 (13074)
steroid 17-alpha-hydroxylase/17,20 lyase (P27786)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Zytiga – Johnson & Johnson
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
38,791 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use